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Abstract
HIV controllers are rare individuals who spontaneously control HIV replication in the absence of antiretroviral treatment.
Emerging evidence indicates that HIV control is mediated through very active cellular immune responses, though how such
responses can persist over time without immune exhaustion is not yet understood. To investigate the nature of memory
CD4+ T cells responsible for long-term anti-HIV responses, we characterized the growth kinetics, Vb repertoire, and avidity
for antigen of patient-derived primary CD4+ T cell lines. Specific cell lines were obtained at a high rate for both HIV
controllers (16/17) and efficiently treated patients (19/20) in response to the immunodominant Gag293 peptide. However,
lines from controllers showed faster growth kinetics than those of treated patients. After normalizing for growth rates, IFN-c
responses directed against the immunodominant Gag293 peptide showed higher functional avidity in HIV controllers,
indicating differentiation into highly efficient effector cells. In contrast, responses to Gag161, Gag263, or CMV peptides did
not differ between groups. Gag293-specific CD4+ T cells were characterized by a diverse Vb repertoire, suggesting that
multiple clones contributed to the high avidity CD4+ T cell population in controllers. The high functional avidity of the
Gag293-specific response could be explained by a high avidity interaction between the TCR and the peptide-MHC complex,
as demonstrated by MHC class II tetramer binding. Thus, HIV controllers harbor a pool of memory CD4+ T cells with the
intrinsic ability to recognize minimal amounts of Gag antigen, which may explain how they maintain an active antiviral
response in the face of very low viremia.
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Introduction
HIV controllers are rare individuals who spontaneously control
HIV replication in the absence of antiretroviral treatment [1,2].
HIV controllers harbor plasma viral loads that remain undetect-
able by conventional assays and cell-associated HIV DNA loads
that are in the very low range, close to one log below those
detected in patients receiving efficient antiretroviral therapy [3–5].
HIV controllers show a very low risk of progression to AIDS [3],
emphasizing the importance of limited viral dissemination in
maintaining a healthy status in the long term.
Emerging evidence indicates that controllers suppress HIV
replication through a very active immunological process. HIV
controllers harbor effector memory CD8+ T cells capable of
rapidly killing infected autologous CD4+ T cells through a
cytotoxic mechanism involving the upregulation of perforin and
Granzyme B [6,7]. Signs of immune activation are more
prominent in HIV controllers than in efficiently treated patients,
and include increased plasma LPS [8], increased expression of T
cell activation markers [9], and increased propensity to secrete
IFN-c and MIP-1b upon polyclonal stimulation [10]. Longitudinal
studies of efficiently treated patients who achieve undetectable
viral load have shown a waning of cellular antiviral responses,
which paralleled the progressive decrease in viral burden [11]. In
contrast, HIV controllers maintain polyfunctional effector mem-
ory T cells with the capacity to secrete multiple cytokines [12–14].
How controllers maintain an active antiviral response in the long
term in spite of a very low viral burden remains poorly understood.
One element contributing to the persistence of an active
immune response may be the quality of the HIV-specific central
memory (CM) compartment. CM T cells are thought to be
responsible for the long-term maintenance of immune memory,
due to their long half-life, high proliferative potential, and capacity
to replenish the pool of effector and effector memory (EM) T cells
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of the CM CD4+ T cell compartment parallels disease progression
in a simian model of AIDS [18]. CM CD4+ T cell functions, such
as proliferation and IL-2 secretion, are impaired as early as the
primary infection stage in progressive HIV infection [19–21], and
are only partially recovered in efficiently treated patients [22,23].
Chronic antigenic stimulation is thought to drive an accelerated
differentiation of CM into effector CD4+ T cells, and thus
contribute to T cell exhaustion. Importantly, CM CD4+ T cell
numbers and functions are preserved in HIV controllers, who
appear protected from this accelerated differentiation process
[24,25]. A recent study suggests that inactivation of pro-apoptotic
molecules may contribute to the remarkable proliferative capacity
of CM CD4+ T cells of HIV controllers, which can exceed that
seen in healthy controls after non-specific stimulation [26].
We have previously shown that signs of CD4+ T cell immune
activation could be detected in HIV controllers who nevertheless
had an intact CM CD4+ T cell compartment, with preserved IL-2
secretion capacity and efficient proliferative responses [10]. How
chronic immune activation was induced in controllers, and why it
did not generally lead to accelerated CD4+ T cell differentiation
and exhaustion remained unclear. To explore these issues, we
tested the capacity of Gag-specific memory CD4+ T cell to
differentiate in vitro, comparing primary CD4+ T cell lines derived
from HIV controllers and efficiently treated patients with
equivalent duration of infection. We found that HIV controller
harbored a pool of memory CD4+ T cells able to differentiate into
effector cells with high functional avidity for an immunodominant
Gag epitope. This heightened sensitivity to Gag antigen could be
explained by a high avidity interaction between the TCR and the
peptide/MHC complex, as measured by class II tetramer binding.
The capacity to mount a CD4 recall response in the presence of
minimal amounts of Gag antigen may help explain how HIV
controllers maintain a continuously activated antiviral response in
spite of very low viremia.
Results
Rapid growth of CD4+ T cell lines from HIV controllers
Memory CD4+ T cell responses were compared in patients who
spontaneously controlled HIV replication (HIC group, n=17) and
in patients who achieved viral control following successful
antiretroviral therapy (HAART group, n=20). Patients in both
groups had viral loads ,40 HIV RNA copies/ml plasma. The
duration of infection and the CD4+ T cell count did not differ
significantly between the two groups (Table 1).
We analyzed the properties of memory CD4+ T cell precursors
by determining their capacity to generate CD4+ T cell lines
specific for three immunodominant HIV-1 Gag peptides (Table 2).
The peptides were chosen because of their broad immunodomi-
nance and their capacity to bind multiple HLA-DRB1 alleles
[20,27–30]. The frequency of response was determined by
measuring the percentage of patients for whom viable CD4+ T
cell lines (defined by a growth ratio .0.7 at day 14) could be
obtained after stimulation with a Gag 20-mer peptide. PBMC
from HIV-seronegative donors did not yield viable cell lines (not
shown). 89 out of 90 cell lines obtained from HIV-seropositive
donors proved peptide-specific, as indicated by a positive IFN-c
response measured in ELISPOT assay. The frequency of response
to the most immunodominant peptide, Gag293, was remarkably
high in both the HIC and HAART groups, with 94% and 95% of
responders, respectively (Table 3). Responses to the second
peptide, Gag263, were also frequent, with 82% responders in
the HIC group and 77% responders in the HAART group. These
findings confirmed that several CD4 epitopes in Gag could achieve
strong immunodominance in patients with controlled HIV-1
infection. Interestingly, responses to the third peptide, Gag161,
were more frequent in the HAART group than in the HIC group,
with 91% versus 53% responders, respectively (P,0.05). We did
not detect an association between the lack of response to Gag161
and particular HLA-DR genotypes. Ex vivo IFN-c ELISPOT
responses to the 3 Gag peptides were low, as expected for CD4
Author Summary
HIV infection, if left untreated, leads to the progressive
disruption of the immune system, the destruction of the
CD4+ T cell population, and the occurrence of multiple
opportunistic infections. However, a small fraction of HIV-
infected individuals (less than 1%) avoid these deleterious
effects by spontaneously controlling HIV replication to
very low levels in the absence of antiretroviral therapy.
Emerging evidence indicates that these rare patients,
named HIV controllers, contain HIV through a very active T
cell-mediated immune response. In this study, we found
that memory CD4+ T cells from HIV controllers had the
capacity to respond to minimal amounts of antigen
derived from the viral protein Gag. This property was
intrinsic to controller CD4+ T cells, and resulted from the
expression of T cell receptors (TCRs) with high avidity for a
particular Gag peptide. The presence of high avidity CD4+
T cells may explain how HIV controllers maintain the
antiviral immune response in constant alert, even though
the amount of virus inducing this response is minimal.
Based on this study, we propose that future candidate
vaccines against HIV should induce high avidity memory
CD4+ T cells, to mimic the rapid and persistent antiviral
response characteristic of HIV controllers.
Table 1. Virological and immunological characteristics of study subjects.
HIV controllers
(HIC, n=17)
Treated patients
(HAART, n=20)
Viremic patients
(VIR, n=10)
Minimal duration of HIV infection, years 15 [10–21] 12 [7–20] 5 [2–9]
Duration of antiretroviral treatment, years - 11 [7–13] -
Viral load, HIV-1 RNA copies/ml plasma ,40 ,40 44,268 [12,500–92,253]
CD4 count, cells/mm
3 blood 741 [256–1207] 786 [422–1534] 430 [150–1087]
CD4+ T cell nadir, cells/mm
3 blood - 305 [11–589] -
Median values [range] are reported.
doi:10.1371/journal.ppat.1000780.t001
High Avidity Memory CD4 T Cells in HIV Controllers
PLoS Pathogens | www.plospathogens.org 2 February 2010 | Volume 6 | Issue 2 | e1000780responses directed to single HIV peptides (Fig. S1). However, it
was interesting to note that 7/13 Controllers had a detectable ex
vivo response to Gag293 while only 1/13 Controller responded to
Gag161 (P,0.05). This finding supported the notion of a higher
frequency of Gag293-specific than Gag161-specific CD4+ T cells
in Controller patients. Taken together, these observations
suggested that the HIV controller status may be associated with
a change in the immunodominance pattern of Gag CD4 epitopes.
As controls, we generated CD4+ T cell lines specific for the
CMV pp65 protein. Since the immunodominance pattern of
CMV responses proved more variable than that observed for
HIV-1, we optimized the generation of CMV-specific CD4+ T cell
lines by choosing the pp65 peptide in function of the HLA DR
genotype of the patients (Table 2) [31–33]. Using this strategy,
close to half of the patients responded to pp65 peptides in both
groups, which was consistent with CMV seroprevalence in the
studied populations.
CD4+ T cell lines typically showed an initial loss of cells due to
apoptosis, followed by growth due to multiplication of HIV- or
CMV-specific cells. Measurement of the growth ratio at day 7
showed that viable CD4+ T cells lines from HIV controllers had a
faster growth kinetics than those from treated patients, with a
significant difference in response to the 3 Gag peptides but not in
response to CMV peptides (Fig. 1A). Analysis of CD4+ T cell lines
derived from a control group of untreated patients with HIV-1
viremia (VIR) showed limited growth capacity in all cases,
consistent with the notion that active HIV-1 replication impaired
the proliferative capacity of memory CD4+ T cells [19].
Measurement of growth ratios at day 14 (Fig. 1B) confirmed the
rapid amplification of controller CD4+ T cell lines in response to
Gag but not to CMV peptides. The clearest differences between
the HIC and HAART groups were seen in response to Gag293
(P=0.003), suggesting that HIV controllers harbored CD4+ T cell
precursors with particularly good proliferative capacity in response
to this immunodominant Gag peptide.
Efficient differentiation of HIV controller CD4+ T cell
precursors
Analysis of IFN-c production by ELISPOT at day 8 showed a
prominent response in HIV controller CD4+ T cell lines (median
SFC/10
6 cells=7,716), while most cell lines from treated patients
remained negative. However, the fact that cell lines from treated
patients had not yet entered the exponential growth phase could
account for these differences. To compare CD4+ T cell lines at
equivalent growth stages, all following measurements were made
at doubling time (mean doubling time=8 days in the HIC group,
13 days in the HAART group, and 14 days in the VIR group). In
these conditions, IFN-c production remained higher in the HIC
group compared to the HAART group in response to the
immunodominant Gag293 peptide (Fig. 2, P=0.006). In control
Table 2. Peptides used to generate CD4+ T cell lines.
Peptide Name Residues Sequence HLA DR genotype of tested patients
HIV peptides
Gag293 293–312 FRDYVDRFYKTLRAEQASQE Tested for all patients
Gag263 263–282 KRWIILGLNKIVRMYSPTSI Tested for all patients
Gag161 161–180 EKAFSPEVIPMFSALSEGAT Tested for all patients
CMV peptides
pp65–509 509–523 KYQEFFWDANDIYRIF HLA-DRB1*0101
00 0 HLA-DRB1*0301
pp65–281 281–295 IIKPGKISHIMLDVA HLA-DRB1*0401
pp65–177 177–191 EPDVYYTSAFVFPTK HLA-DRB1*0701
pp65–489 489–507 AGILARNLVPMVATVQGQN HLA-DRB1*1101
pp65–41 41–55 LLQTGIHVRVSQPSL HLA-DRB1*1501
pp65–489 489–507 AGILARNLVPMVATVQGQ HLA-DRB5*0101
doi:10.1371/journal.ppat.1000780.t002
Table 3. Frequency of memory CD4+ T cell responses.
Peptides HIV controllers (HIC) Viremic patients (VIR) Treated patients (HAART)
Gag293 94% (16/17) 70% (7/10) 95% (19/20)
Gag263 82% (14/17) 57% (4/7) 77% (10/13)
Gag161 41% (8/15)* 0% (0/6)*** 92% (12/13)
pp65 CMV
a 57% (9/14) 80% (4/5) 44% (8/18)
The frequency of obtention of a CD4+ T cell line with a positive IFN-g response is indicated in %.
The number of patients with a positive CD4+ T cell response reported to the number of patients tested is indicated in parentheses.
atotal of responses to CMV peptides.
Differences in frequency were evaluated by Fisher’s exact test.
*P,0.05 (HIC vs HAART).
***P,0.0005 (VIR vs HAART).
doi:10.1371/journal.ppat.1000780.t003
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PLoS Pathogens | www.plospathogens.org 3 February 2010 | Volume 6 | Issue 2 | e1000780Figure 1. Rapid Growth of CD4+ T cell lines from HIV controllers. Growth of viable CD4+ T cell lines specific for Gag293, Gag263, Gag161 and
CMV peptides was measured in groups of HIV controllers (HIC), viremic patients (VIR), and treated patients (HAART). The growth ratio, corresponding to
the numberof observed cells divided by the numberof input cells, was evaluated at day 7 (A)and day 14 (B)of culture. Each symbol corresponds to one
subject. Horizontal bars indicate medians. All statistically significant differences (P,0.05) evaluated by the Mann-Whitney U test are reported on graphs.
doi:10.1371/journal.ppat.1000780.g001
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signal, confirming that IFN-c was produced by CD4+ T cells, and
not by the CD8+ T cells that may have escaped CD8 depletion
(Fig. S2).
IFN-c ELISPOT responses measured at doubling time were
higher in the HIC group than in the VIR group for all peptide
tested (Fig. 2). However, we and others have previously shown that
when responses are measured ex vivo, which gives an evaluation of
ongoing effector responses, CD4+ T cells from viremic patients
produce as much IFN-c as those of HIV controllers, while CD4+
T cells from treated patients have low IFN-c production
[10,11,22,24]. The hierarchy of IFN-c responses measured after
proliferation of CD4+ T cell memory precursors is different, and
rather reflects the capacity of these precursors to differentiate into
cells with effector functions. We conclude that HIV controllers
harbor memory CD4+ T cell precursors that can differentiate into
efficient cytokine-secreting cells.
Increased functional avidity of memory CD4+ T cells from
HIV controllers
To assess the sensitivity of memory CD4+ T cells to antigenic
stimulation, we measured IFN-c production in response to serial
peptide dilutions (Fig. 3). We did not observe a significant
difference in the dose of Gag293 peptide that induced a half-
maximal ELISPOT response (median EC50=1.38 10
26 Mi n
HIC vs. 1.55 1026 M in HAART, P=0.09). However, we
observed that the shapes of the response curves differed, with a
marked trailing end in the HIC group, suggesting the presence of a
high avidity component within the responding CD4+ T cell
population (see representative examples in Fig. 3A and Fig. S3).
To extend this observation, we measured the last peptide
concentration that gave a positive ELISPOT reading at least 2
fold above background. We verified that measurement of this
concentration was reproducible in duplicate experiments (Table
S1). Importantly, all measurements were carried out on CD4+ T
cell lines at doubling time, to normalize for growth stage.
This analysis revealed that the functional avidity of CD4+ T
cells recognizing the immunodominant Gag293 peptide was
higher in HIV controllers (Fig. 3B). In the HIC group, 10 out of
15 patients tested had a positive ELISPOT reading at peptide
concentrations #51 0
28 M, while in the HAART group only 1
out of 17 patients tested had a positive response at the same
concentrations (P=0.005). In contrast, functional avidities mea-
sured for Gag263, Gag161, and CMV peptides did not differ
significantly between groups. These results pointed to a particular
efficiency of CD4+ T cells specific for the immunodominant
Gag293 in HIV controllers. Interestingly, the functional avidity of
these cells correlated with the level of the IFN-c response
measured by ELISPOT assay at high peptide dose (R=20.68,
P,0.0001). Thus, CD4+ T cells responses to Gag293 appeared
both sensitive and potent in the group of controller patients.
Increased frequency of the HLA-DRB*0701 allele in HIV
controllers
Patients were genotyped for the HLA DRB1 gene at 4 digit
resolution. Table 4 reports the frequency of the most common
HLA DRB1 alleles among the 34 HIV controllers and the 34
efficiently treated patients who were genotyped at initiation of the
Figure 2. Increased IFN-c production by CD4+ T cell lines from HIV controllers. Production of IFN-c by CD4+ T cell lines specific for Gag293,
Gag263, Gag161 and CMV peptides were compared between groups of HIV controllers (HIC), viremic patients (VIR), and treated patients (HAART).
IFN-c production was measured by ELISPOT assay on CD4+ T cell lines restimulated with peptide, and was expressed by the number of spot forming
cells (SFC) per million cells. All measurements were made at CD4+ T cell line doubling time. Horizontal bars indicate medians. All statistically
significant differences (P,0.05) evaluated by the Mann-Whitney U test are reported on graphs.
doi:10.1371/journal.ppat.1000780.g002
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PLoS Pathogens | www.plospathogens.org 5 February 2010 | Volume 6 | Issue 2 | e1000780Figure 3. Increased functional avidity of memory CD4+ T cells from HIV controllers. The functional avidity was evaluated by IFN-c ELISPOT
assay in the presence of decreasing peptide concentrations (serial dilutions from 4610
26 Mt o1 0
211 M). For each peptide dilution, IFN-c production
was expressed as the number of spot forming cells (SFC) per million cells. The functional avidity was defined as the last peptide dilution that gave a
positive IFN-c response at least 2 fold above background level. (A) Representative examples of functional avidity measurement in response to Gag293
for one HIV controller (HIC) and one treated patient (HAART). The peptide dilution at half response (EC50) and the last positive peptide dilution are
indicated. (B) Functional avidity of CD4+ T cell lines specific for Gag293, Gag263, Gag161 and CMV peptides were compared between groups of HIV
controllers (HIC), viremic patients (VIR), and treated patients (HAART). All measurements were made at CD4+ T cell line doubling time. Horizontal bars
indicate medians. All statistically significant differences (P,0.05) evaluated by the Mann-Whitney U test are reported on graphs.
doi:10.1371/journal.ppat.1000780.g003
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44% in the controller group and 18% in the treated patient group,
which yielded a significant difference as measured by Fisher’s
exact test (P=0.03). No other DRB1 allele showed significant
differences. The frequency of the DRB1*0701 allele in the French
population was reported to be 26% [34], close to that seen in the
group of treated patients. In contrast, the frequency of
DRB1*0701 appeared increased among HIV controllers.
To further explore the possibility that DRB7*0701 conferred an
advantage in CD4+ T cell memory function, we compared
functional parameters in DRB1*0701 positive versus DRB1*0701-
negative individuals included in the study. We did not detect
significant differences within the HIC group in terms of growth
ratio, IFN-c response, or functional avidity of CD4+ T cells
following Gag293 stimulation. Within the HAART group,
DRB1*0701-positive individuals showed lower IFN-c responses
(median SFC/10
6 cells=2458, n=6) than DRB1*0701-negative
individuals (median SFC/10
6 cells=6116, n=9, P=0.02). Taken
together, these findings suggest that the DRB1*0701 allele may
confer an increased chance to acquire a controller phenotype
upon HIV infection, but that once the controller phenotype is
established, the presence of the DRB1*0701 allele does not confer
further benefit in terms of CD4+ T cell function.
Rapid proliferation of Gag293-specific CD4+ T cells from
HIV controllers
To further characterize the nature of Gag293-specific CD4+ T
cells, we identified these cells through MHC class II tetramer
labeling. Analysis of Gag293-specific CD4+ T cell lines revealed
the presence of tetramer-positive (Tet+) cells for all the patients
tested, confirming the antigen specificity of the cell lines
(representative examples in Fig. 4A and 4B), and the capacity of
the Gag293 peptide to bind multiple HLA-DR alleles [27]. At
doubling time, the frequency of Tet+ cells was in the order of 1%.
(Fig. 4A). The population of tetramer-negative (Tet2) cells may
correspond to Gag293-specific cells restricted by an HLA-DR, -
DP, or DQ allele distinct from that used in the tetramer, or to cells
amplified through bystander effect. At later time points, the
population of Tet+ cells could reach up to half of the CD4+ T cells
(Fig. 4B), suggesting an efficient amplification of Gag293-specific
cells restricted through HLA-DR. Comparison of the percentage
of Tet+ cells at doubling time showed no significant difference
between the HIC and HAART groups (Fig. 4C), which validated
our normalization strategy. Namely, CD4+ T cell lines analyzed at
equivalent growth stages contained equivalent numbers of peptide-
specific cells, and could thus be usefully compared.
To determine the proliferative capacity of Tet+ cells, Gag293-
specific CD4+ T cell lines were labeled with CFSE at doubling
time and analyzed by flow cytometry 3 days later (Text S1,
supplementary methods). The percentage of CD4+ Tet + cells that
had divided (CFSElo) was comparably high for the 3 HIC and 3
HAART cell lines analyzed (Fig. S4). The proliferative index,
which represents the average number of divisions undergone by
the population that divided, showed a trend toward higher values
in the HIC cell lines. Interestingly, the difference became more
apparent when the number of cells that had undergone 5 divisions
or more was computed. In HAART cell lines, 6 to 7% of Tet+
cells had undergone 5 or more divisions, while in HIC cell lines
these percentages were of 40%, 35%, and 18%. These data
suggested that Tet+ cells from HIV controllers comprised a
population endowed with an intrinsically high proliferative
capacity and a short generation time.
Diverse repertoire of HIV-specific CD4+ T cells in HIV
controllers
The TCR Vb specificities of Tet+ and Tet2 cells within CD4+
T cell lines were determined at doubling time by immunostaining
with a panel of anti-Vb antibodies (Fig. 5A and B). The TCR Vb
repertoire of Gag293-specific CD4+ T cells was diverse in both the
HIC and HAART groups and varied depending on the individual.
Table 5 lists the Vb specificities showing an amplification within
the Tet+ population, as defined by a ratio Tet+/Tet2$ 4i na
Tet+ population $2% of CD4+ T cells. The frequency of
amplified Vb populations is reported in supplementary Table S2.
This analysis showed that Vb1 was amplified in 3 out of 4 cell lines
in the HAART group and in 2 out of 4 cell lines in the HIC group.
Vb9 and Vb13.2 were also amplified in half of cell lines tested.
These observations suggest that some Vb chains may be
preferentially selected in response to the Gag293 peptide.
However, we did not detect a Vb signature characteristic of the
HIC group. Taken together, these data suggest that multiple
clones contribute to the high avidity memory CD4+ T cell
population in HIV controllers.
Increased TCR avidity of memory CD4+ T cells in HIV
controllers
The high functional avidity of controller CD4+ T cells could
result from increased avidity of the TCR for the pMHC complex,
or from multiple factors that facilitate APC/T cell interactions or
effector functions, including expression tuning of costimulatory
molecules or efficiency of the IFN-c secretion system [35]. To
explore this issue, we set to directly test the avidity of the TCR/
pMHC interaction. The TCR avidity was evaluated by measuring
the percentage of Gag293-specific Tet+ CD4+ T cells detected as
a function of decreasing class II tetramer concentrations, as
described in reference [36] (Fig. 6A). The concentration measured
at half-binding (EC50) did not show significant differences between
the HIC and HAART groups. However, the shape of the binding
curves differed between groups, with a persistence of detectable
binding at low tetramer concentrations in the HIC group (Fig. 6B).
The TCR avidity was measured by the inverse of the last
concentration that gave a Tet+ staining at least 2 fold higher than
control CLIP-tetramer staining. Comparison of Gag293-specific
CD4+ T cells at doubling time showed that the TCR avidity was
Table 4. Phenotypic frequency of HLA DRB1 alleles in study
subjects.
HLA DRB1 allele
HIV controllers
(n=34)
Treated patients
(n=34)
DRB1*0101 15% (5) 21% (7)
DRB1*0301 3% (1) 18% (6)
DRB1*0401 12% (4) 12% (4)
DRB1*0701
a 44% (15) 18% (6)
DRB1*1101 12% (4) 6% (2)
DRB1*1301 18% (6) 15% (4)
DRB1*1501 12% (4) 24% (8)
The frequency of individuals positive for a given HLA DRB1 allele is indicated in
%.
The number of positive individuals is indicated in parentheses.
Differences in frequency were evaluated by Fisher’s exact test.
Comparisons were made only for alleles present in 4 or more individuals in the
controller group or the treated patient group.
a: a significant difference was detected for the DRB1*0701 allele (P,0.05).
doi:10.1371/journal.ppat.1000780.t004
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PLoS Pathogens | www.plospathogens.org 7 February 2010 | Volume 6 | Issue 2 | e1000780Figure 4. Characterization of HIV specific CD4+ T cells by MHC class II tetramer staining. (A) Representative examples of class II tetramer
staining for Gag293-specific CD4+ T cells in cell lines at doubling time. Four distinct tetramers corresponding to alleles DRB1*0101, DRB1*0401,
DRB1*0701 and DRB5*0101 were loaded with the Gag293 peptide and used to stain CD4+ T cell lines from HIV controllers (HIC) and treated patients
(HAART) with matching HLA DR alleles. Negative controls corresponding to cell lines labeled with a DR-matched CLIP-loaded tetramer are shown for
the 4 HAART cell lines. (B) Class II tetramer staining for Gag293-specific CD4+ T cells in cell lines from two HIV controllers (HIC) after 18 days of culture,
showing the amplification of the tetramer+ population. (C) The percentage of Gag293-specific tetramer+ cells in CD4+ T cell lines at doubling time
did not differ significantly between the HIC and HAART groups, as evaluated by the Mann-Whitney U test.
doi:10.1371/journal.ppat.1000780.g004
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(Fig. 6C), indicating a difference in the nature of CD4+ T cell
clones responding to the immunodominant Gag293 epitope. Thus,
the high functional avidity of HIV controller CD4+ T cells could
be explained, at least in part, by an intrinsic property of their
TCR.
Discussion
This study provides evidence that HIV controllers harbor a pool
of high avidity memory CD4+ T cell precursors directed against
an immunodominant Gag peptide. Memory CD4+ T cells specific
for the Gag293 peptide were endowed with rapid growth potential
and, importantly, with IFN-c secretion capacity, suggesting that
they would rapidly generate a pool of CD4+ T cells with effector
function upon antigenic stimulation in controller patients. The
high functional avidity of Gag293 specific cells points to their
capacity of initiating recall responses in the presence of minimal
amounts of HIV antigen. The high functional avidity could be
explained, at least in part, by a high avidity interaction between
the TCR and the cognate Gag293 peptide/MHC complex. Thus,
the high sensitivity of controller CD4+ T cells to antigen appeared
intrinsic, rather than dependent on the antigen presentation
context or the cytokine milieu. The Vb repertoire of tetramer-
positive Gag293-specific cells proved diverse, suggesting that
multiple clones contributed to the high avidity CD4 response in
HIV controllers. This property may favor the long-term
persistence of a high avidity response, since the presence of
multiple clones reduces the probability of viral escape or of
immune senescence. Taken together, these findings suggest that
Figure 5. Gag293-specific CD4+ T cells have a diverse Vb repertoire. (A) Example of TCR Vb staining: comparison of three Vb specificities in
the tetramer-negative (left panel) and tetramer-positive (right panel) CD4+ T cell populations obtained for a Gag293-specific cell line from an HIV
controller. In this case, Vb13.6 expression is amplified in the tetramer-positive population. (B) Example of Vb repertoire analysis in an HIV controller
CD4+ T cell line at doubling time. The clonogram indicates the percentage of CD4+ T cells labeled with a given Vb-specific antibody within the
tetramer-negative (black bars) and tetramer-positive (red bars) populations. The presence of multiple Vb specificities within tetramer-positive
population indicates that Gag293-specific CD4+ T cells have a diverse Vb repertoire.
doi:10.1371/journal.ppat.1000780.g005
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group of controller patients. We propose that the rapid triggering
of recall responses may contribute to viral control. A rapid CD4+
T cell response upon occurrence of ‘‘viral blips’’ will keep the
immune system in alert, provide immediate help for CD8+ T cells
to exert efficient cytotoxic function, and possibly provide direct
antiviral effector function [37]. This rapid recall response may
help keep HIV-1 replication under a low threshold, and avoid the
progressive undermining of the immune system associated with
repeated viral replication episodes [38].
The presence of high avidity CD4+ T cells helps explain how
HIV controllers maintain an active T cell response in the face of
very low viremia. We and others have previously shown that the
level of the specific CD4+ T cell responses in HIV controllers
exceeds that seen in efficiently treated patients, even though both
groups have very low antigenemia [10,11,22,24]. The triggering of
recall responses at very low antigenic load in the controller group
may account for this difference. Emerging evidence suggests that
the CD8+ T cell response may also be of high avidity in HIV
controllers. In particular, individuals harboring the protective
HLA-B27 allele frequently develop a high avidity response against
the immunodominant KK10 CD8 epitope, the avidity of the
response correlating inversely with viral load [39]. The fact that
HIV controllers maintain antiviral CD8+ T cells with high
cytotoxic potential in spite of their low viral load is also suggestive
of a high avidity response [6,7,40]. Thus, both the CD4+ and the
CD8+ T cell compartments may contribute to the high sensitivity
to antigen characterizing antiviral responses in the controller
group. Studies in mouse models of chronic viral infections have
shown that efficient CD8 responses do not persist in the long term
without CD4 help [41]. Therefore, a high avidity CD4 response
may be essential in maintaining the quality of the CD8 response in
low viremia conditions.
A correlate of a heightened sensitivity to HIV antigens may be a
chronic level of immune activation, due to the recall of cellular
responses upon each viral replication episode, however limited.
Indeed, we have previously reported on signs of ongoing immune
activation in the effector memory CD4+ T cell compartment of
HIV controllers, as measured by the expression of HLA-DR, the
downregulation of the IL-7 receptor, and the secretion of MIP-1b
[10]. Other signs of activation include raised levels of LPS in
plasma [8] and increased expression of HLA-DR within the HIV-
specific CD8+ T cells [6] as compared to efficiently treated
patients. These observations confirm the notion that viral control
is achieved through an active immunological process. One should
note that excessive chronic activation may be deleterious in the
long term, as suggested by a trend toward CD4+ T cell decrease in
controller patients with the highest degree of immune activation,
even in the persistence of undetectable viral load [9]. It will be
important in future studies to determine if such individuals show a
decrease in T cell functional avidity, which may lead to more
prolonged induction of recall responses to achieve viral control,
and consequently to prolonged episodes of immune activation. On
the other end of the activation spectrum, a few controllers appear
to have low HIV-specific CD8 responses and a generally quiescent
immune system [42]. This phenotype may result from a
particularly successful viral control, with an antigenemia so low
that it would not activate the high avidity memory T cell
population for long periods of time. It also remains possible that
non-T cell based, alternate mechanisms of viral control predom-
inate in these rare individuals.
It was intriguing that HIV controllers responded less frequently
to the Gag161 peptide than efficiently treated patients, while the
quality of the CD4+ T cell response appeared generally better in
the former group. This observation pointed to possible changes in
the immunodominance pattern associated with the controller
status. Responses to Gag161 may have become subdominant in
the controller group due to competition by high avidity CD4+ T
cells responding to other epitopes, including that present in the
Gag293 peptide. Indeed, high avidity has been shown to sharpen
immunodominance in mouse models [43]. The key mechanism
appears to be the increased proliferative capacity of high avidity T
cells, which progressively fill the memory T cell niche, a
phenomenon accounting for the apparent avidity maturation of
T cell responses over time [36,44]. Importantly, in the present
study, the duration of HIV-1 infection in the group of efficiently
treated patients did not differ significantly from that in the
controller group, with median of 12 (7–20) vs. 15 (10–21) years,
respectively. Thus, a longer infection time was unlikely to account
for the presence of high avidity CD4+ T cells in the controller
group.
The CFSE analysis identified a population of Gag293-specific
cells with high proliferative capacity in HIV Controller cell lines,
which was consistent with the presence of a pool of high avidity
CD4+ T cells. The number of divisions undergone by Tet+ cells
Table 5. TCR Vb amplification ratios in Gag293-specific CD4+
T cell lines.
Vb specificity HIV controllers Treated patients
# 1 # 2 # 3 # 4 # 1 # 2 # 3 # 4
1 - 5 5-7 -6 6
2 - -------
3 - -------
4 - --2 6 ----
5 . 1 - -58 ---1 8
5 . 2 71 5 ------
5 . 3 1 3 7 ---2 6 --
7.1 - 7 - - 21 - 15
7 . 2 - -------
8 - -------
9 1 6 7 ---6 -1 4
1 1 - -------
1 2 - -3 9 ---7 -
1 3 . 1 - ---2 5 ---
1 3 . 2 54 ----5 2 5
1 3 . 6 - 9 4-2 0 ---
1 4 - -------
1 6 - -4 0 -----
1 7 - -------
1 8 - -------
2 0 - -5-----
2 1 . 3 - -------
2 2 - -5-----
23 - 4 - 8 - 20 - -
Total number of
Vb amplifications
4 7833435
The ratio of tetramer-positive (Tet+) to tetramer-negative (Tet2) CD4+ T cells is
given for each of the 24 Vb specificities tested.
Only ratio $4 in populations of Tet+ cells $2% are reported.
doi:10.1371/journal.ppat.1000780.t005
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and above. This may reflect a range of avidities for the Gag293
antigen, with only a fraction of Tet+ cells being endowed with high
avidity and thus high proliferative capacity. This notion is also
supported by the shape of the functional avidity curves, which
suggests the presence of both high and low avidity populations
within the pool of Gag293-specific cells from HIV Controllers.
However, the high avidity component was absent in the Gag293-
specific CD4+ T cell population from treated patients, indepen-
dent of the method of analysis (functional avidity, tetramer avidity,
or proliferation of Tet+ cells). One should note that the growth
ratio of CD4+ T cell lines depended on the intrinsic proliferative
capacity of specific cells but also on the frequency of these specific
cells at the initiation of culture. We have previously shown that the
frequency of p24 Gag-specific cells measured ex vivo by
intracellular cytokine staining was approximately 3 fold higher in
HIV controllers than in efficiently treated patients [10]. The
analysis of ex vivo ELISPOT responses to the Gag293 peptide also
showed a trend for higher values in the controller group. Thus, it is
likely that both an increased precursor frequency and a higher
proliferative capacity contributed to the efficient growth of CD4+
T cell lines from HIV controllers. Both properties may also
contribute to the long term persistence of CD4 responses in these
patients.
The genetic background may play a role in conferring a better
ability to mount high avidity CD4+ T cell responses. The
increased frequency of HLA DRB1*0701 in the controller group
could suggest a beneficial effect of this allele on the development of
anti-HIV CD4 responses. However, since we did not detect an
association between the presence of HLA DRB1*0701 and the
level or avidity of the CD4 response within the controller group,
we speculate that this allele may play a role in initially facilitating
viral control, rather than in maintaining high avidity CD4+ T
cells. Alternatively, HLA DRB1*0701 may be in linkage
disequilibrium with a protective MHC class I allele associated
with viral control. A beneficial effect of the HLA DRB1*13 alleles
on CD4 responses has also been suggested [13,20], though we did
not detect a significant effect in our study. It will be important to
confirm these findings in cohorts of patients powered for large
scale genetic studies. An intrinsic advantage in CD4+ T cell
growth capacity may also promote efficient CD4 responses in
controllers. Van Grevenynghe et al. [26] have reported an
increased growth capacity of controller CD4+ T cell lines in
response to polyclonal stimulation, as compared to cell lines
derived from efficiently treated patients or even from healthy
donors. These authors demonstrated a role for the activation of the
PI-3 kinase pathway, and the resultant inactivation of the
downstream apoptosis inductor FOXO3a, in this particular
growth phenotype. We did note a trend for higher growth ratios
in controller CD4+ T cell cultures in the presence of CMV
peptides, even in the absence of a positive IFN-c ELISPOT
response (not shown). However, an increase in growth propensity
only partially accounts for the CD4 response characteristics
observed in HIV controllers. High avidity CD4+ T cells were
directed against HIV but not CMV, pointing towards a selective
advantage in the induction of anti-HIV responses.
The selection of high avidity gag-specific CD4+ T cells may
result from a lower exposure to HIV antigens during the acute
infection stage, when the repertoire of responding T cells is initially
shaped. The few reported cases of acute HIV-1 infection followed
by spontaneous viral control support the notion of a lower viral
peak in patients who acquire a controller status [45]. Mouse
Figure 6. Increased TCR avidity of memory CD4+ T cells in HIV controllers. (A) The TCR avidity of Gag293-specific CD4+ T cells was
determined by MHC class II tetramer staining in the presence of decreasing tetramer concentrations. An example shows the progressive decrease of
Gag293-DRB1*0101 tetramer staining as a function of tetramer concentration in an HIV controller CD4+ T cell line at doubling time. (B) Representative
examples of TCR avidity measurement in Gag293-specific CD4+ T cell lines from one HIV controller (HIC) and one treated patient (HAART). The
tetramer dilution at half response (EC50) and the last positive tetramer dilution are indicated. (C) The TCR avidity was defined as the inverse of the last
tetramer dilution that gave a positive staining at least 2 fold above control CLIP-tetramer staining. The TCR avidity of Gag293-specific CD4+ T cell lines
was significantly higher in the controller group (HIC) than in the treated patient group (HAART) as evaluated by the Mann-Whitney U test. Horizontal
bars indicate medians.
doi:10.1371/journal.ppat.1000780.g006
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development of a high avidity response, since only the high avidity
T cells receive sufficient signals through the TCR to proliferate in
the long term [44,46]. Such a scenario may predominate in
patients who spontaneously control HIV replication. The presence
of high avidity T cells may in turn stabilize the controller status by
limiting viral replication episodes.
On the other hand, we cannot rule out that high avidity Gag-
specific CD4+ T cells are selected but subsequently lost in
progressor patients. Since high avidity CD4+ T cells are the first to
respond in the presence of low HIV antigen amounts, they may be
the first to get activated in the presence of replicating HIV, and
may represent the initial wave of target cells available to the virus.
HIV is known to preferentially infect HIV-specific cells [47], and
among those it may well preferentially infect the most readily
activated population. A recent report suggests that responses to
several CD4 epitopes can be detected during the acute infection
stage but are subsequently lost in progressor patients, which
supports the idea of a rapid culling of the CD4 repertoire [21].
Another reason for the loss of high avidity CD4+ T cells may be
senescence due to overstimulation by high antigenic loads in
progressor patients. The observation that high avidity CD8
responses can be lost after acute HIV infection supports such a
model [48]. An important area of future research will be to
elucidate mechanisms that protect high avidity CD4+ T cells from
depletion in HIV controllers.
In conclusion, this study provides evidence for the presence of
high avidity CD4+ T cells directed against Gag in HIV controllers.
It is remarkable that the distinctive properties of HIV-specific T
cells in Controllers, including high proliferative potential
[14,24,49], polyfunctionality [12,13] and high cytotoxic capacity
per cell [6,7], are all known attributes of high avidity T cells
[36,40,50,51]. Thus, high avidity may underlie many of the
characteristics of an efficient adaptive immune response against
HIV. The presence of high avidity T cells has been associated with
control of chronic viral infections in mice [50,52], monkeys [53],
and humans [54]. Since high avidity also confers long-term
memory and rapid reactivation in presence of antigen [36,44,55],
it represents a desirable property to be induced by candidate T cell
vaccines against HIV.
Materials and Methods
Patients
HIV controllers (HIC group; n=17) were recruited through the
French ‘‘Observatoire National des HIV Controllers’’ established
by ANRS. HIV controllers were defined as HIV-1 infected
patients who had been seropositive for .10 years, had received no
antiretroviral treatment, and for whom .90% of plasma viral load
measurements were ,400 copies of HIV RNA/ml. All HIV
controllers included in the present study had current viral loads
,40 copies/ml. Control groups included: (1) HAART group
(n=20): HIV-1 infected patients successfully treated with
antiretroviral therapy for more than 5 years and with a viral load
,40 copies of HIV RNA/ml; (2) VIR group (n=10): viremic
patients with viral loads .10,000 copies HIV RNA/ml. Viremic
patients had been infected with HIV-1 for more than 1 year and
had not received antiretroviral therapy. Patients from the HAART
and VIR groups were recruited through the SEROCO-
HEMOCO cohort and the Bice ˆtre hospital.
Ethics statement
The study was promoted by ANRS under number EP36 and
approved by the Comite ´ de Protection des Personnes IDF VII
under number 05–22. All participants gave written informed
consent prior to blood sampling.
Derivation of CD4+ T cell lines
PBMC from HIV infected patients were plated at 2610
6 cells
per well in 24-well plates in the presence of one HIV-1 Gag or
pp65 CMV peptide (10 mM) in RPMI 1640 supplemented with
10% human AB serum, 2 mM L-glutamine, 10 mM HEPES,
100 ug/ml penicillin/streptomycin, 0.5 mM AZT, 5 nM Saquin-
avir and 5 ng/ml recombinant IL-7 (Cytheris). The peptides used
to stimulate the culture were highly purified 20-mers (.99%
purity; PolyPeptide Laboratories). Recombinant IL-2 was added
after 2 days to a final concentration 100 U/ml. Cell lines were
restimulated with IL-2 every 2 days until the end of culture.
Starting from day 7, cells were counted every day by trypan blue
exclusion to determine the growth ratio (GR: observed number of
cells/number of input cells at day 0). The CD8+ T cell population
represented a median of 5.9% (range: 0–22.7%) of the CD3+
population. CD8+ T cells were depleted with magnetic beads
(IMag particles, BD Biosciences) at doubling time (GR=2), before
performing functional assays. Less than 1% CD8+ T cells
remained after CD8 depletion (Fig. S2A).
ELISPOT assay
IFN-c secretion by CD4+ T cell lines was evaluated by
ELISPOT assay as previously described [56]. Briefly, 96-well
nitrocellulose plates were coated with 1 mg/ml anti-human IFN-c
capture monoclonal antibody (Mabtech). Cell lines starved off IL-2
for 16 h were plated in duplicate at 30,000 cells/well in coated
ELISPOT plates and incubated with 4 mM peptide for 24 h at
37uC. Wells were then washed, incubated with a biotinylated anti-
IFN-g detection antibody (Mabtech), followed with alkaline
phosphatase-labeled extravidin (Sigma-Aldrich), and with a
chromogenic alkaline phosphatase-conjugated substrate. IFN-c
spot-forming cells (SFC) were counted with a Bioreader 4000
system (Bio-Sys). The ELISPOT response was expressed as SFC/
10
6 cells after subtracting background. Wells were counted as
positive if the number of SFC was at least two times above
background level. Functional avidity assays were carried out on all
cell lines with ELISPOT responses .1000 SFC/10
6 PBMC.
ELISPOT responses were measured in response to serial peptide
dilutions from 4610
26 to 10
211 M, and the last dilution that gave
a number of SFC at least two times above background was
determined.
MHC class II tetramer labeling
At initiation of the study, 34 HIV controllers and 34 treated
patients were genotyped for HLA-DRB1. Patients were included
in the study if their genotype matched at least one of the 6 HLA-
DRB1 alleles available for MHC class II tetramer studies. This
panel allowed the analysis of $70% of Caucasian patients [34].
PE-labeled tetramers for the DRB1*0101, DRB1*0301,
DRB1*1501 and DRB5*0101 alleles were obtained through the
NIH Tetramer Facility at Emory University. HLA-DRB1*0401,
DRB1*0701, and DRB1*1101 biotinylated monomers were
produced in insect cell cutures as previously described [57–59].
Monomers were loaded with 0.2 mg/ml peptide by incubation at
37uC for 72 h in the presence of 2.5 mg/ml n-octyl-b-D-
glucopyranoside and 1 mM Pefabloc SC (Sigma-Aldrich). Pep-
tide-loaded monomers were tetramerized using APC- or PE-
conjugated streptavidin (eBioscience). To each tetramer loaded
with the Gag293 peptide corresponded a control tetramer loaded
with the CLIP peptide.
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CD4+ T cell lines were incubated with 4 mg/ml class II tetramer for
90 min at 4uC in PBS-1% BSA buffer. Surface marker antibodies
CD4-PerCP, CD3-AF750-APC, CD14-FITC (eBioscience), CD8-
FITC, CD19-FITC (BD Biosciences), and the Aqua Live/Dead
viability dye (Invitrogen) were added for the last 20 min of labeling.
The percentage of tetramer-positive (Tet+) cells was measured in the
live, CD3+,C D 4 +,C D 8 2,C D 1 4 2, CD19-gate. Events were
acquired on a CyAn flow cytometer (Beckman Coulter, Fullerton,
CA) and analyzed using the Flowjo software (Tree Star). Negative
controls were obtained by staining with HLA-DR matched
tetramers loaded with the CLIP peptide. To determine the avidity
of the TCR/pMHC interaction, CD4+ T cell lines were incubated
with decreasing concentrations of class II tetramer from 1 to
0.01 mg/ml. The avidity was defined as the inverse of the last
concentration that gave a percentage of Tet+ cells at least 2 fold
higher than CLIP-tetramer control values.
TCR Vb repertoire analysis
The TCR Vb repertoire of HIV-specific CD4+ T cell lines was
determined by co-staining cells with an MHC class II tetramer and
a panel of Vb-specific antibodies (IOt-Test Beta Mark TCR Vb
repertoire kit, Beckman Coulter), according to the manufacturer’s
instructions. The kit covered approximately 70% of human Vb
specificities. The Vb nomenclature is that of Wei et al. [60]. A Vb
specificity was considered amplified when the Vb frequency was
increased at least 4 fold in the Tet+ compared to the Tet-
population. A ratio of 4 was above the range of Vb variation
observed in the ex vivo repertoire of HIV-infected patients [61] and
within the range of Vb expansions induced by superantigens in vitro
[62].
Statistical analysis
Data are expressed as medians and range. Analyses were
performed with the GraphPad Prism 5.0 software, using
nonparametric statistical tests in all cases. Differences in variables
between groups were analyzed with the Mann-Whitney U Test.
Differences in percentages of response were analyzed with the
Fisher’s exact test. Correlations were analyzed with Spearman’s
coefficient R. All significant differences between groups (P,0.05)
were reported on data plots.
Supporting Information
Text S1 Supplementary methods and figure legends.
Found at: doi:10.1371/journal.ppat.1000780.s001 (0.03 MB
DOC)
Figure S1 Analysis of ex vivo IFN-c ELISPOT responses in
PBMC from HIV controllers and efficiently treated patients.
Production of IFN-c by PBMC stimulated with Gag293, Gag263,
and Gag161 20-mer peptides was measured in HIV controllers
(HIC; n=13) and treated patients (HAART; n=6). IFN-c
production was measured by ELISPOT assay on PBMC plated
at 10
5 cells/well and stimulated with 4 mM peptide for 24 h. IFN-
c production was expressed as the number of spot forming cells
(SFC) per million cells. Horizontal bars indicate medians. All
statistically significant differences (P,0.05) evaluated by the
Mann-Whitney U test are reported on graphs.
Found at: doi:10.1371/journal.ppat.1000780.s002 (0.31 MB EPS)
Figure S2 Control experiments demonstrating that IFN-c
production is mediated by CD4+ T cells. (A) Representative
examples of the efficacy of CD8+ T cell depletion: The expression
of CD4 and CD8 within the CD3+ T cell population was
evaluated in Gag293-specific cell lines from two HIV controllers
(HIC1 and HIC2). CD8+ T cells present in cell lines at doubling
time (top row) were depleted with anti-CD8 coated magnetic
beads. Less than 1% CD8+ T cells remained in the CD3+
population after depletion (bottom row). (B) Comparison of
ELISPOT responses before and after CD8 of CD4 depletion:
Gag293-specific CD4+ T cells lines from one HIV controller
(HIC) and one treated patient (HAART) were evaluated at
doubling time for IFN-c production by ELISPOT assay. ELI-
SPOT responses were measured on cell lines before depletion (No
depletion), after depletion of CD8+ cells (CD82), or after
depletion of CD4+ cells (CD42). The cellular concentration was
normalized to 30,000 cells per well prior to ELISPOT analysis.
IFN-c production was expressed as the number of spot forming
cells (SFC) per million cells. (C) Additional examples demonstrat-
ing that CD4 depletion abrogated the ELISPOT response:
Gag293-specific cells lines from 3 treated patients were depleted
either for CD8 or for CD4 prior to evaluation of IFN-c production
by ELISPOT assay.
Found at: doi:10.1371/journal.ppat.1000780.s003 (0.49 MB
EPS)
Figure S3 Representative examples of functional avidity
measurements in response to Gag and CMV peptides. (A)
Functional avidity in Gag293-specific cell lines was evaluated at
doubling time by ELISPOT assay. Representative examples are
shown for 3 HIV controllers (HIC) and 3 treated patients
(HAART). Functional avidity was measured by IFN-c ELI-
SPOT assay in the presence of decreasing peptide concentra-
tions (serial dilutions from 4610
26 Mt o1 0
211 M). For each
peptide dilution, IFN-c production was expressed as the number
of spot forming cells (SFC) per million cells. The functional
avidity was defined as the last peptide dilution that gave a
positive IFN-c response at least 2 fold above background level.
(B) Representative examples of functional avidity measurements
in response to Gag263, Gag161 and CMV peptides. Cell lines
from one HIV controller and one treated patient were analyzed
in each case.
Found at: doi:10.1371/journal.ppat.1000780.s004 (0.64 MB EPS)
Figure S4 Analysis of the proliferative capacity of Gag293-
specific cells. Gag293-specific CD4+ T cell lines from 3 treated
patients (HAART) and 3 HIV controllers (HIC) were labeled at
doubling time with CFSE. The Gag293-specific Tetramer+
CD4+ CD3+ population was analyzed 3 days later by flow
cytometry. The number of generations was evaluated by the
decrease in CFSE labeling. CFSE histograms were fitted with
models that separated the populations into individual genera-
tions, using the FlowJo v8.8 software. The modeled generations
are represented in dark blue, and the resulting curve fit is
represented in red. ‘‘% divided’’ is the percentage of cells in the
original sample which divided. ‘‘Proliferation index’’ is the
average number of divisions undergone by the cells which
divided (it does not take into account generation 0). Also reported
in red is the percentage of cells that have undergone 5 or more
divisions. This parameter highlights the presence of a population
of Gag293-specific cells with high proliferative capacity in HIV
controller cell lines.
Found at: doi:10.1371/journal.ppat.1000780.s005 (0.99 MB EPS)
Table S1 Reproducibility of functional avidity measurements.
Found at: doi:10.1371/journal.ppat.1000780.s006 (0.04 MB XLS)
Table S2 Frequencies of amplified TCR Vb in CD4+ T cell
lines specific for the Gag293 peptide.
Found at: doi:10.1371/journal.ppat.1000780.s007 (0.03 MB XLS)
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